-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At present, most cancer vaccines treat cancers that have already appeared in patients by stimulating the response of the human immune system
Triple-negative breast cancer patients account for 15-20% of breast cancer patients, and it is more common in women under the age of 40
This new cancer vaccine targets a breast-specific lactating protein called α-lactalbumin
Preclinical studies have shown that activating the immune response to α-lactalbumin can safely and effectively prevent breast cancer in a mouse model
The upcoming phase 1 clinical trial will enroll 18 to 24 patients.
The researchers proposed that subsequent trials will involve healthy, cancer-free women at high risk of breast cancer, who voluntarily undergo bilateral mastectomy to reduce their risk of cancer
Reference materials:
[1] Cleveland Clinic Launches First-of-its-Kind Preventive Breast Cancer Vaccine Study.
[2] Jaini, R.
(The original text has been deleted)